Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06015750
Other study ID # D8400C00001
Secondary ID AA-HPP-4072022-5
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date April 30, 2024
Est. completion date April 28, 2028

Study information

Verified date April 2024
Source Alexion Pharmaceuticals, Inc.
Contact Alexion Pharmaceuticals, Inc. (Sponsor)
Phone 1-855-752-2356
Email clinicaltrials@alexion.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the effect of immunosuppressive therapy (IST) in participants treated with asfotase alfa who demonstrate immune-mediated loss of effectiveness (LoE).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 8
Est. completion date April 28, 2028
Est. primary completion date April 28, 2028
Accepts healthy volunteers No
Gender All
Age group 2 Years to 18 Years
Eligibility Inclusion Criteria: - Reoccurrence or worsening of rickets for at least the past 3 months in participants who showed an initial efficacy response to asfotase alfa after at least 6 months of continuous treatment and currently receiving asfotase alfa. RSS will be used to determine severity at Baseline. - Presence of ADAs, with or without NAbs, irrespective of their titers. - Confirmation by the TMB that both the clinical evidence and immunogenicity-mediated association noted above are present. - Female participants of childbearing potential and male participants with partners of childbearing potential must follow protocol-specified contraception guidance as described in Section 10.5. - Participant, or participant's legal guardian, is capable of signing informed consent or assent as described in Section 10.1.3, which includes compliance with the requirements and restrictions listed in the informed consent or assent form and in this protocol. Exclusion Criteria: - Known history of human immunodeficiency virus (HIV) infection (evidenced by HIV type 1 or type 2 [HIV 1, HIV 2] antibody) or hepatitis B or C viral infection. - Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to Screening. - Inability of the participant, or the participant's legal guardian, to provide informed consent. - Pregnant, breastfeeding, or intending to conceive during the course of the study. - Inability to travel to the clinic for specified visits during the Treatment Period caused by disease per se or logistics (does not apply to external travel restrictions). - The participant is at risk of reactivation or has an active significant viral infection such as hepatitis B, cytomegalovirus, herpes simplex, human polyomavirus (also known as John Cunningham [JC] virus), parvovirus, or Epstein Barr virus. - The participant is at risk of reactivation of tuberculosis or has regular contact (eg, in the household) with individuals who are being actively treated for tuberculosis. - The participant has had or is required to have any live vaccination within 1 month prior to enrollment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
methotrexate
Methotrexate will be administered SC or orally weekly for 104 weeks.
rituximab
Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.
bortezomib
Bortezomib will be administered via IV bolus or SC, as needed.
IVIg
IVIg will be administered via IV monthly through initial 74 weeks.
Folic Acid
Folic acid will be given orally as long as methotrexate is being dosed.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Alexion Pharmaceuticals, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Achieve Immunosuppressive Therapy (IST) Complete Response at Week 100 Week 100
Secondary Number Participants with Antidrug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) Baseline Through Week 100
Secondary ADA and NAb Titer Levels Baseline Through Week 100
Secondary Serum Concentration of Asofatase Alfa (Measured as Enzyme Activity) Baseline Through Week 100
Secondary Plasma Concentration of Pyridoxal-5'-Phosphate (PLP) Baseline Through Week 100
Secondary Plasma Concentration of Inorganic Pyrophosphates (PPi) Baseline Through Week 100
Secondary Number of Participants with Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events Baseline Through Week 104
See also
  Status Clinical Trial Phase
Completed NCT03418389 - Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia
Recruiting NCT02237625 - Natural History Study of Patients With Hypophosphatasia (HPP)
Completed NCT02291497 - Burden of Disease in Hypophosphatasia (HPP) N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Active, not recruiting NCT04195763 - Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)
Not yet recruiting NCT05596539 - Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)
Completed NCT02751801 - Health Burden of Hypophosphatasia
Completed NCT02796885 - Characterisation of Adult-Onset Hypophosphatasia
Completed NCT05890794 - Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia Phase 1/Phase 2
Recruiting NCT06079359 - Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP Phase 3
Recruiting NCT05234567 - A Prospective Sub-Study of the Global Hypophosphatasia Registry
Completed NCT02797821 - Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP) Phase 2
Completed NCT01163149 - Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP) Phase 2
Completed NCT04925804 - Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)
Completed NCT02531867 - Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan Phase 4
Completed NCT01406977 - Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP) Phase 2
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT01176266 - Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP) Phase 2/Phase 3
Withdrawn NCT00894075 - Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) Phase 2
Active, not recruiting NCT04222452 - The PORTRAIT Study